Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
0.00%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 697 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Indaptus Therapeutics, Inc.
Market Cap
$285.94M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$284.21M
Gross Margin
0.00%
TTM Avg
10.38%
3Y Avg
-887.42%
5Y Avg
-730.43%
Market Cap
$289.25M
Gross Margin
73.68%
TTM Avg
36.84%
3Y Avg
49.00%
5Y Avg
66.00%
Market Cap
$290.79M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$280.60M
Gross Margin
42.62%
TTM Avg
48.63%
3Y Avg
38.13%
5Y Avg
25.55%
Market Cap
$290.97M
Gross Margin
49.14%
TTM Avg
49.09%
3Y Avg
45.86%
5Y Avg
49.48%
Market Cap
$278.87M
Gross Margin
-94.12%
TTM Avg
-431.85%
3Y Avg
-231.35%
5Y Avg
-189.25%
Market Cap
$276.08M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$297.62M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $285.94M | 0.00% | 0.00% | 0.00% | 0.00% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $284.21M | 0.00% | 10.38% | -887.42% | -730.43% |
| Abeona Therapeutics Inc. (ABEO)vs › | $289.25M | 73.68% | 36.84% | 49.00% | 66.00% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $290.79M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aurora Cannabis Inc. (ACB)vs › | $280.60M | 42.62% | 48.63% | 38.13% | 25.55% |
| Standard BioTools Inc. (LAB)vs › | $290.97M | 49.14% | 49.09% | 45.86% | 49.48% |
| Fate Therapeutics, Inc. (FATE)vs › | $278.87M | -94.12% | -431.85% | -231.35% | -189.25% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $276.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $297.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.27M | 93.41% | 92.41% | 88.66% | 85.93% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-30 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-30 | 0.00% |
